| abstract |
"COMPOUND, PRO-DRUG PROCESS TO PRODUCE A COMPOUND, PHARMACEUTICAL COMPOSITION METHOD FOR ANTAGONIZING AN ADENOSIN A3 RECEPTOR, TO INHIBIT P38 MAP KINASE AND THE PRODUCTION OF TNF-ALFA AND TO PREVENT OR TREAT DISEASES AND USE." The optionally oxidized compounds in N represented by the general formula (I) their salts which are usable as preventives or remedies for diseases in association with the adenosine receptor A3 because they have excellent antagonism to the adenosine receptor A3 in which R ^ 1 ^ represents hydrogen, hydrocarbyl, a heterocycle, amino or acyl; R ^ 2 ^ represents an aromatic group; R ^ 3 ^ represents hydrogen, pyridyl or aromatic hydrocarbyl; X represents oxygen or optionally oxidized sulfur; Y represents a bond, oxygen, optionally oxidized sulfur or NR ^ 4 ^ (where R ^ 4 ^ represents hydrogen, hydrocarbyl, or acyl); and Z represents a bond or a divalent chain hydrocarbyl. In addition, compounds (1) or their salts exhibit excellent effects of inhibiting p38MAP kinase and inhibiting TNF- <244> and therefore are also usable as preventives or remedies for diseases in association with p38MAP kinase or TNF- <244 >. |